Type 2 Diabetes Trial, Recruiting NCT04932928 Sponsor: Seoul National University Hospital Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT04932928
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 19 and 80 years old.
  • People who have been diagnosed with type 2 diabetes.
  • People whose type 2 diabetes is not well controlled, with a blood sugar level (HbA1c) between 7.0% and 10.0% — this is a measure of average blood sugar over the past few months.
  • People who have signed a form agreeing to take part in the trial.

Who may not be able to join:

  • People diagnosed with any other type of diabetes, such as type 1 diabetes.
  • People currently using fast-acting (mealtime) insulin.
  • People who have had a change in their diabetes medications in the past 3 months.
  • Women who are pregnant or breastfeeding.
  • People with a drug or alcohol addiction.
  • People taking medications known to raise blood sugar levels, such as steroids.
  • People with severe liver disease.
  • People with advanced kidney failure who are on dialysis.
  • People who are unable to wear a continuous glucose monitor (a small skin sensor that tracks blood sugar) due to skin problems, such as severe burns, serious skin infections, severe skin reactions, or excessive hair growth at the sensor site.
  • People with certain medical conditions that affect the accuracy of HbA1c blood sugar readings (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Young Min Cho, MD, PhD, Seoul National University Hospital

Phone: 82-2-2072-1965

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
23 March 2021
Est. completion
23 September 2022

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Change in HbA1c

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov